LGND (Ligand Pharmaceuticals Incorporated) Company Projected Revenue

Ligand (LGND) - corporate logo

The investment attractiveness of Ligand Pharmaceuticals (LGND) is based on stable royalties from an extensive patent portfolio. The company's projected sales dynamics clearly confirm this trend, where this metric equals 1.19. Its status as a reliable partner for leading laboratories and unique methods for increasing molecular solubility strengthen the brand's position, while strict FDA oversight and the complexity of replicating Captisol technologies create an insurmountable barrier to entry for competitors.

LGND - Ligand Corp Company Future Sales over the range 07/04/2022 - 11/18/2026

Analytical breakdowns for Ligand Pharmaceuticals

- stock value and consensus price forecast:
- business market valuation indicators:
Summary company analytics:Ligand Pharma
Brand item of Ligand Pharma

The market assesses the investment potential of Ligand Pharmaceuticals (LGND) as moderately risky, given the current value of 1.19. This metric aggregates expected shipment volumes considering global market transformations; therefore, the projected sales trajectory reflects the sensitivity of royalties to the commercial success of partners and regulatory pressure in the US, determining the fundamental value of this biopharmaceutical asset.

Who Ligand Pharmaceuticals competes with

Projected Sales Volume HLN|KVUE (Kenvue Inc) - Company Future Revenue|Verona Pharma Corp - Company Future Sales Volume|Company Projected Revenue Volume MENS (Jyong Biotech Ltd)|AMRX - Company Projected Revenue|Company Expected Sales Volume perrigo.com|ALVO (Alvotech SA) - Company Future Sales Volume|Company Sales Forecast Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Projected Sales Volume|ANIP: Company Future Revenue|Company Projected Revenue Afrezza (MNKD)|Projected Sales Volume amphastar.com (AMPH)|Projected Sales Volume PCRX (pacira.com)|Company Future Revenue SPRY|Theravance Biopharma Inc - Projected Sales Volume|Company Future Sales Aquestive Therapeutics AQST|SCPH: Projected Sales Volume|Company Future Sales Volume Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Projected Sales Volume|SXTC (China SXT Pharmaceuticals, Inc.) - Company Projected Revenue Volume|Company Projected Revenue eupraxiapharma.com (EPRX)|Company Projected Revenue Volume BHST|Company Projected Revenue eXoZymes EXOZ|Company Future Revenue ORMP|ENTX - Company Projected Revenue|HYFT: Company Projected Revenue|ABVC BioPharma, Inc (ABVC) - Company Projected Revenue|Cumberland Pharma - Company Future Revenue|QNTM (Quantum BioPharma Corp) - Projected Sales Volume|FibroGen, Inc. - Company Expected Revenue|Projected Sales Volume TELO|Company Future Sales Rani Therapeutics Holdings, Inc.|Company Projected Revenue Synergy CHC Corp. SNYR|Projected Sales Volume rallybio.com RLYB|Lexaria Bioscience Corp. - Projected Sales Volume|PULM: Company Projected Revenue|PTHL (ftzy.com.cn) - Company Future Sales Volume|APM: Company Projected Revenue Volume|LYRA (Lyra Therapeutics Inc) - Projected Sales Volume|Company Revenue Forecast IBO (Impact BioMedical)|Company Future Sales Volume TNFA (TNF Pharmaceuticals)|Projected Sales Volume cbdMD Corp (YCBD)|Projected Sales Volume PRFX (PainReform)|Company Future Sales Auris Medical (CYTO)|LIPO - Company Projected Revenue|Optinose (OPTN) - Company Future Sales Volume|Pieris (PIRS) - Company Projected Revenue|Company Expected Revenue PROC (Procaps Group S.A.)|Company Future Sales Volume PTPI|QLI: Company Future Revenue|Company Projected Revenue acelyrin.com (SLRN)|TFFP (TFF Pharma) - Company Future Revenue